Investor Presentation Q1 2022
6
Investor presentation
First three months of 2022
Diabetes value market leadership increased by 1.2%-points to
30.5%
Novo Nordisk global diabetes value market share
Diabetes value market leadership expansion
driven by the GLP-1 franchise
60%
⚫Diabetes
GLP-1
-Insulin
53,6%
50,8%
50%
48,3%
46,1%
44,0%
44,5%
44,1%
44,0%
40%
29,3%
30,5%
•
30%
28,0%
28,8%
0%
2019
2020
2021
2022
CER: Constant exchange rates; IO: International Operations; NAO: North America Operations
Source: IQVIA MAT, Feb 2022 (Spot rate)
Note: Sales growth rates are at CER
Diabetes care sales grew by 16% with global value market share
increase driven by GLP-1 market share gains in both IO and NAO
Insulin volume market share has decreased from 47.2% to 47.0% in the
last 12 months
GLP-1 value market share has increased by 2.8%-points in the last 12
months, driven by:
OzempicⓇ launches and uptake in 72 countries
RybelsusⓇ uptake in North America Operations and launches in
International Operations
Novo NordiskⓇView entire presentation